

ACTION: Notice of Proposed New Routine Use in OGE/GOVT-1 System of Records.

SUMMARY: The U.S. Office of Government Ethics (OGE) proposes to add a new Routine Use to OGE/GOVT-1, Executive Branch Personnel Public Financial Disclosure Reports and Other Name-Retrieved Ethics Program Records. This action is necessary to comply with the requirements of the Privacy Act to publish in the **Federal Register** notice of the existence and character of records maintained by the agency (5 U.S.C. 552a(e)(4)). OGE last published OGE/GOVT-1 in 68 FR 3097-3109 (January 22, 2003), as corrected at 68 FR 24744 (May 8, 2003).

DATES: This action will be effective without further notice on June 1, 2011 unless comments received before this date would result in a contrary determination.

ADDRESSES: You may submit comments to OGE on this Privacy Act Notice by any of the following methods:

E-mail: usoge@oge.gov (Include reference to "Privacy Act New Routine Use Comment" in the subject line of the message).

Fax: 202-482-9237, Attention: Elaine Newton, Privacy Officer.

Mail, Hand Delivery/Courier: Office of Government Ethics, Suite 500, 1201 New York Avenue, NW., Washington, DC 20005-3917, Attention: Elaine Newton, Privacy Officer.

FOR FURTHER INFORMATION CONTACT: Ms. Newton at the Office of Government Ethics; telephone: 202-482-9265; TTY: 800-877-8339; FAX: 202-482-9237; E-mail: enewton@oge.gov.

SUPPLEMENTARY INFORMATION: In accordance with the Privacy Act of 1974, 5 U.S.C. 552(a), this document provides public notice that the OGE is proposing to adopt a new Routine Use (l.) in OGE/GOVT-1, Executive Branch Personnel Public Financial Disclosure Reports and Other Name-Retrieved Ethics Program Records. This addition will not affect any Privacy Act rights afforded individuals who are the subject of such records. The new Routine Use is being proposed to provide relevant and necessary information to Federal Government Web sites and to any person in support of the Ethics in Government Act of 1978, 5 U.S.C. app. 110; the conflicts of interest criminal statutes, 18 U.S.C. 202-209; the Standards of Ethical Conduct for Employees of the Executive Branch, 5 CFR part 2635; Memorandum on Transparency and Open Government, 74 FR 4685 (Jan. 26, 2009); and in support of this Administration's core principles

of the business of government, transparency, participation, collaboration and innovation.

The system report, as required by 5 U.S.C. 552a(r), has been submitted to the Committee on Homeland Security and Governmental Affairs of the United States Senate, the Committee on Oversight and Government Reform of the House of Representatives and the Office of Management and Budget.

Routine Use (l.)

(l.) to disclose on the OGE Web site and to otherwise disclose to any person, including other departments and agencies, any written ethics agreements filed with the Office of Government Ethics, pursuant to 5 CFR 2634.803, by an individual nominated by the President to a position requiring Senate confirmation when the position also requires the individual to file a public financial disclosure report.

Approved: April 25, 2011.

Robert I. Cusick,

Director, Office of Government Ethics.

[FR Doc. 2011-10628 Filed 4-29-11; 8:45 am]

BILLING CODE 6345-03-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Funding Opportunity Announcement DD11-005, Initial Review

Correction: This notice was published in the **Federal Register** on April 11, 2011, Volume 76, Number 69, Page 19995. The time for the aforementioned meeting has been changed to the following:

Time: 11 a.m.-5 p.m.

Contact Person for More Information: Brenda Colley Gilbert, Ph.D., M.P.H., Director, Extramural Research Program Office, National Center for Chronic Disease Prevention and Health Promotion, CDC, 1600 Clifton Road, NE., Mailstop K92, Atlanta, Georgia 30333, *Telephone:* (770) 488-6295.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 26, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011-10546 Filed 4-29-11; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 76 FR 15984-15985, dated March 22, 2011) is amended to reflect the reorganization of the National Center on Birth Defects and Developmental Disabilities, Office of Noncommunicable Diseases, Injury and Environmental Health, Centers for Disease Control and Prevention.

Section C-B, Organization and Functions, is hereby amended as follows:

Delete item (7) of the functional statement for the Office of the Director (CUB 1), National Center on Birth Defects and Developmental Disabilities (CUB) and insert the following: (7) serves as primary liaison between NCBDDD and the CDC Office of the Associate Director for Communications and its associated research and practice.

Following the title and functional statement for the Division of Human Development and Disability (CUBC), insert the following:

Office of the Director (CUBC1). (1) Provides leadership and guidance on strategic planning and implementation, program priority setting, and policy development, to advance the mission of the division, NCBDDD, and CDC; (2) develops goals, objectives, and budget; monitors progress and allocation of resources, and reports accomplishments, future directions, and resource requirements; (3) facilitates scientific, policy and program collaboration among divisions and centers, and between CDC and other federal/non-federal partners; (4) promotes advancement of science throughout the division, supports program evaluation, and ensures that research meets the highest standards in the field; (5) provides medical expertise